论文部分内容阅读
目的研究琥珀酸索利那新治疗女性患者膀胱过度活动症的有效性及安全性。方法 90例女性膀胱过度活动症患者,随机分为对照组及试验组,各45例。对照组采取酒石酸托特罗定片治疗,试验组给予琥珀酸索利那新治疗,比较两组治疗前及治疗后2、4周膀胱过度活动症症状表(OABSS)评分以及不良反应情况。结果两组治疗后OABSS评分均优于治疗前(P<0.05);治疗4周后试验组OABSS评分(4.5±1.87)分优于对照组(5.6±1.78)分,差异有统计学意义(P<0.05)。试验组不良反应率为6.67%,低于对照组的22.22%,差异有统计学意义(P<0.05)。结论使用琥珀酸索利那新治疗女性膀胱过度活动症临床疗效高,不良反应率低,值得推广。
Objective To study the efficacy and safety of solifenac succinate in the treatment of overactive bladder in female patients. Methods Ninety female patients with overactive bladder were randomly divided into control group and trial group, with 45 cases in each group. The control group was treated with tolterodine tartrate, and the experimental group was given solifenac sodium succinate. OABSS scores and adverse reactions in both groups before and after 2,4 weeks of treatment were compared. Results OABSS scores of both groups were better than those before treatment (P <0.05). After 4 weeks of treatment, the score of OABSS in test group (4.5 ± 1.87) was superior to that of control group (5.6 ± 1.78), P <0.05). The rate of adverse reactions in the experimental group was 6.67%, which was lower than that in the control group (22.22%), the difference was statistically significant (P <0.05). Conclusions The use of solifenacin succinate in the treatment of female overactive bladder has high clinical efficacy and low adverse reaction rate, which deserves promotion.